A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2018-07-01
Target enrollment:
Participant gender:
Summary
Given the role of mTOR signaling and probable synergistic activity of combining sirolimus and
metformin in patients with advanced solid tumors, the investigators hypothesize that:
1. The combination of metformin plus sirolimus will result in reduction of p4EBP1, p70S6K
and pAKT more than sirolimus alone in peripheral blood T cells (PBTC).
2. The combination of metformin plus sirolimus will result in decreased levels of serum
biomarkers including fasting insulin, C-peptide, glucose, triglycerides, LDH, IGF-1,
IGF-1R, IGF-BP and leptin, but an increase in adiponectin in peripheral blood.
3. Expression of active forms of AMPK, mTOR, PI3K, PTEN loss, AKT, LKB1, P62, LC3, and/or
ULK1 in the tumor tissue (original pathology) will be predictive of response to
combination therapy. This will be an exploratory hypothesis for this study.
4. Sirolimus induced toxicity, especially hyperglycemia and hypertriglyceridemia, will be
mitigated by combining sirolimus with metformin.
5. Metformin plus sirolimus will have promising anti-cancer activity and this activity will
correlate with decreases in the above biomarkers. This will be an exploratory hypothesis
for this study.